CT 1812

Drug Profile

CT 1812

Alternative Names: CT1812

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cognition Therapeutics
  • Class Antidementias; Small molecules
  • Mechanism of Action Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Alzheimer's disease
  • Phase I Cognition disorders

Most Recent Events

  • 23 Aug 2017 Cognition Therapeutics completes the phase Ib/II COG0102 study in Alzheimer's disease (In adults, In the elderly) in Australia (PO)
  • 31 Jul 2017 Cognition Therapeutics completes patient enrolment in a phase Ib/II trial in Alzheimer's disease in Australia (PO) before July 2017
  • 19 Jul 2017 Drug interactions and adverse event data from the phase I COG01013 trial in Healthy volunteers presented at the 2017 Alzheimer’s Association International Conference (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top